Loading...
XLON
AVCT
Market cap442mUSD
Jul 09, Last price  
70.50GBP
1D
1.44%
1Q
0.71%
Jan 2017
-2.08%
IPO
-93.53%
Name

Avacta Group PLC

Chart & Performance

D1W1MN
XLON:AVCT chart
P/E
—
P/S
2,922.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.13%
Rev. gr., 5y
-44.49%
Revenues
113k
0.00%
4,000212,000466,000944,0002,067,0002,445,0003,130,0002,700,0003,180,0001,813,0002,165,0002,735,0002,763,0003,890,1042,144,0002,941,0009,653,0002,851,000113,000113,000
Net income
-38m
L-27.37%
-107,000-1,219,000-1,468,400-2,685,000-1,879,000-591,000-1,106,000-1,521,000-1,492,000-10,139,000-4,647,000-6,367,000-8,829,000-11,022,316-18,891,000-26,316,000-36,940,000-24,947,000-52,841,000-38,376,000
CFO
-25m
L+4.89%
-139,000-1,250,000-1,295,000-2,799,000-1,741,000-596,000-711,000-1,377,000-838,000-2,515,000-4,233,000-4,241,000-5,468,000-13,015,000-10,642,000-20,506,000-16,432,000-14,872,000-23,597,000-24,751,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.
URL
https://avacta.com/
IPO date
Sep 08, 2003
Employees
120
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT